Izidakamizwa Ze-Blockbuster Ongazibuka Esikhathini Esizayo Esiseduze

I-Clarivate Plc, okuyinkampani yomhlaba wonke ekuhlinzekeni ngolwazi nemininingwane yokusheshisa ijubane lokusungula izinto ezintsha, namuhla imemezele ukukhishwa kombiko wayo waminyaka yonke we-Drugs to Watch™, ehlonza izidakamizwa ezingena emakethe noma yethula izinkomba ezibalulekile ngo-2022 okubikezelwa ukuthi zizofinyelela isimo se-blockbuster by. 2026. Ukusebenzisa I-Clarivate idatha kanye nemininingwane, abahlaziyi bahlonze ukwelashwa kokuhlolwa kwesigaba sekwephuzile okuyisikhombisa ababikezela ukuthi kuzoletha izindali zonyaka ezingaphezu kuka-$1 bhiliyoni phakathi neminyaka emihlanu. Lezi zindlela zokwelapha zithatha isethi ehluke ngokuphawulekayo yezindawo zokwelapha, kusukela ezimeni ezifana nesifo i-Alzheimer's (AD), isifuba somoya kanye nohlobo 2 lwesifo sikashukela (T2DM), esihlupha amashumi ezigidi zeziguli emhlabeni wonke, kuya ezifweni ezingavamile, njenge-transthyretin amyloidosis (ATTR) , phakathi kwabanye.

Lo mbiko uphinde unikeze ukuhlaziya okujulile kwemithi yokugomela kanye nezindlela zokwelapha ezibalulekile ze-COVID-19 kanye nezindawo ezibalulekile zokuthuthukiswa kokwelapha okufanele zibukwe, njengokwelashwa kwamaseli nofuzo, i-CRISPR, ukutholwa kwezidakamizwa okuqhutshwa ubuhlakani bokwenziwa nokufunda ngomshini, i-RNA kanye nemithi yokwelapha yomdlavuza ehlosiwe. . Ngaphezu kwalokho, umbiko uhlola izidakamizwa ze-blockbuster kanye ne-biologics ebhekene nokuncintisana kwamajenerikhi ngenxa yokuphelelwa yisikhathi kwelungelo lobunikazi lase-US ngo-2022.

Ukuzulazula endaweni yokunakekelwa kwezempilo yomhlaba kuya ngokuya kuba nzima, futhi ukuthola, ukuthuthukisa kanye nokudayisa izindlela zokwelapha eziphumelelayo ezishintsha izimpilo zesiguli kungaba inselele, ikakhulukazi ezikhathini zanamuhla ezingakaze zibonwe ngaphambili. Umbiko we-Drugs to Watch ugqamisa ukwelapha okuhlolwayo ngesithembiso esihle sokuthola imiphumela ethuthukisiwe yesiguli kanye nemizamo yokuxhasa ngezimali isizukulwane esilandelayo semithi emisha. Ngokuzivumelanisa nezimo, ukuthuthukiswa kanye nezixazululo ze-crowdsourcing, izinkampani ezilandela lezi zindlela zokwelapha ezithembisayo zithuthukisa uhlu olubanzi lwabafuna ukwelashwa okusha - besebenzisa ubuchwepheshe obujulile ezindaweni zabo zokwelapha ezifanele kanye namasu esikhathi eside wokuphishekela izixazululo zokwelapha zalezi zimo.

Phakathi kwemithi emisha nama-biologics azuze ukugunyazwa noma alungele ukukwenza, i-Clarivate ihlonze ukwelashwa okuyisikhombisa ekholelwa ukuthi kungase kuzuze isimo se-blockbuster eminyakeni emihlanu ezayo. Izidakamizwa zango-2022 okufanele zibukwe, zihlanganisa:

• I-Adagrasib, ithuthukiswe yi-Mirati Therapeutics Inc kanye ne-Zai Lab Limited - Lokhu kwelashwa okuhlosiwe okulindelwe isikhathi eside kungase kube inketho yokuqala enjalo yokwelashwa ezigulini ezinomdlavuza we-colorectal (CRC) ezinokuguqulwa kwe-KRASG12C, ngokomlando ebezinezinketho zokwelashwa ezimbalwa kakhulu. Izinhlobonhlobo ezivamile ze-oncoprotein ye-KRAS ngokuvamile zibhekwa njengezinhloso zezidakamizwa ezingalawuleki okwenza ukufakwa okubikezelwe kwe-KRAS inhibitor ezigulini ezinamathumba aqinile aguquguqukayo abe mkhulu kakhulu.

• Faricimab, ithuthukiswe yi-Roche and Chugai Pharmaceutical - Ezigulini ezine-diabetic macular edema (DME) noma i-macular degeneration ehlobene neminyaka emanzi (AMD), i-faricimab inikeza inketho engase ibe lula kakhulu njengoba izophathwa kancane, ngokwesilinganiso, kunezinga lokunakekelwa. . Njenge-antibody yokuqala ye-bispecific eyethulwa ku-ophthalmology, futhi inamandla okusebenza ngempumelelo kunezinga lamanje lokunakekela, nakuba idatha kuze kube manje ibonisa ukuthi ayikho ngaphansi kwezinga lokunakekelwa. I-Faricimab iyisivimbeli sokuqala esimbaxambili se-VEGF/Ang-2 sokwelapha i-DME ne-AMD emanzi (kanye ne-bispecific MAb yokuqala endaweni yokwelapha ye-ophthalmology iyonke).

• I-Lecanemab, ithuthukiswe yi-Eisai Co Ltd kanye ne-Biogen Inc, kanye ne-donanemab, evela kwa-Eli Lilly and Company - Kule makethe enganakekile, i-anti-Aβ MAbs lecanemab kanye ne-donanemab bakulungele ukulandela ezithendeni zophawu olungokomlando lwe-US FDA olusheshisa ukugunyazwa kwe-ADUHELM ukuze zelashwe AD. I-Lecanemab ne-donanemab zinganikeza amaphrofayili omtholampilo ahlukene, angase aqiniswe imiphumela yesigaba sesi-3 okulindeleke ukuthi kubikwe kusukela ngasekupheleni kuka-2022. Idatha kuzo zonke izivivinyo zomtholampilo iphakamisa ukuthi ukuchayeka okwanele kumithamo ephezulu yokwelashwa kwe-anti-Aβ MAb kungase kusebenze ngokomtholampilo ekuqaleni AD.

• I-Tezepelumab, ithuthukiswe yi-Amgen kanye ne-AstraZeneca – I-Tezepelumab iwushintsho lomdlalo olungase lube khona ezigulini ezinesifuba somoya okungeyona i-TH2 noma i-TH2-low isifuba somoya esinesifuba somoya esingalawulwa kahle nge-corticosteroids ehogeliwe, izinga lamanje lokunakekelwa. Uma kuvunyiwe, kuzoba i-biologic yekilasi lokuqala kulesi sibalo sesiguli. I-Tezepelumab cishe izoba i-biologic yomugqa wokuqala yesifuba somoya esinamandla se-TH2-low kanye nenketho yokwelapha ezigulini ezine-TH2-high asthma lezo izindlela zokwelapha ezikhona ezingaphumelelanga kangako.

• I-Tirzepatide, ithuthukiswe ngu-Eli Lilly kanye neNkampani - i-Tirzepatide inikeza ukuncipha okuhamba phambili okuyizinkomba ekulahlekelweni kwesisindo kanye nokuthuthukiswa kokulawulwa kwe-glycemic kubantu abakhulayo besiguli, okunamandla okunciphisa ubungozi bezinkinga ezihlobene nohlobo lwe-2 yesifo sikashukela (T2DM). Ukwelashwa okusha okungabhekana ngokuphumelelayo nokuncipha kwesisindo nokulawulwa kwe-glycemic kunokwelashwa okukhona kungase kube yinzuzo enkulu emiphumeleni yesiguli.

• Vutrisiran, ithuthukiswe yi-Alnylam Pharmaceuticals – Ngesifo esiqhubekayo esinesidingo esiningi esingahlangatsheziwe, lo muthi uletha ukusebenza kahle, iphrofayili yokuphepha evumayo ngokuvamile, kanye nentuthuko ekulethweni okuzozuzisa izinga lempilo yesiguli. Lesi sibalo sesiguli sinezinketho ezimbalwa zokwelapha, ikakhulukazi kulabo abanohlobo lwasendle lwe-ATTR. Lo muthi awugcini nje ngokungena emakethe lapho kuqhathaniswa nezinye, futhi unomthamo ongcono kakhulu kuneminye imithi eqondene ne-ATTR emakethe.

UMike Ward, Inhloko Yomhlaba Wonke Yezesayensi Yezempilo Nobuholi Bemicabango Yezempilo, Clarivate: “Ngenkathi izinkampani ezenza imithi kanye ne-biotech zitshale izimali ezinkulu zobuhlakani kule minyaka emibili edlule zibhekana nezinselelo ezidalwe yi-COVID-19, ziqhubekile nokusebenzisa ubuchwepheshe obusha ukuze bakhe. Imithi ezonikeza izinketho ezigulini ezinezifo ezimbi noma ezingelapheki okwamanje ezisamele umthwalo omkhulu wezokwelapha. Izinketho zalo nyaka zokubukwa kwezidakamizwa, kanye nokukhetha kobuchwepheshe ozobukwa, kugqamisa ukuqamba okusha okusenhliziyweni yomkhakha wezamakhemisi ne-biotech futhi kuzosekela imiphumela engcono ezigulini esikhathini esizayo.”

Naphezu kokuthi ubhubhane lwe-COVID luphazamise imboni yezidakamizwa ngezindlela eziningi, kusukela ekushodeni okubangelwa ukuwa kwe-supply chain kwezingxenye ezibalulekile1 kuya ekubambezelekeni kwesivivinyo somtholampilo2, izinkampani zekhemisi kanye ne-biotech ziyaqhubeka nokuqhuba intuthuko enkulu kwezokwelapha. Abenzi bezidakamizwa benza igxathu elikhulu ekuvuleni ubuchwepheshe obuzolekelela imithi yomuntu siqu. Abalawuli bakhombisa ukuvuleleka kubuchwepheshe obusha nezindlela kanye nokulangazelela ukubhekana nezifo ezitholakala kalula noma okungekho nhlobo ukwelashwa kwazo. Kodwa-ke, kusabalulekile ukuthi izinkampani zibonise ukubaluleka kwazo ukuze zizuze ukugunyazwa kwemakethe futhi zizenze zifinyeleleke ezigulini.